Research analysts at Wedbush started coverage on shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) in a research report issued to clients and investors on Thursday. The firm set a “neutral” rating and a $132.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price would indicate a potential downside of 1.26% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Jefferies Group reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, May 29th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, June 26th. Leerink Swann reiterated a “buy” rating and set a $200.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 8th. Credit Suisse Group AG upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Saturday, July 9th. Finally, Cowen and Company reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $180.54.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 2.55% on Thursday, hitting $133.69. The company had a trading volume of 1,175,592 shares. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45. The stock has a market cap of $29.98 billion, a PE ratio of 335.90 and a beta of 1.08. The company has a 50-day moving average of $131.16 and a 200 day moving average of $135.82.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing the consensus estimate of $1.17 by $0.04. The business had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. Alexion Pharmaceuticals’s revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.44 EPS. Analysts anticipate that Alexion Pharmaceuticals will post $4.65 EPS for the current fiscal year.

In related news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $45,530.48. Following the completion of the transaction, the chief executive officer now owns 189,266 shares of the company’s stock, valued at approximately $25,955,939.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Heidi L. Wagner sold 222 shares of the firm’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $30,445.08. Following the completion of the transaction, the senior vice president now directly owns 32,115 shares of the company’s stock, valued at approximately $4,404,251.10. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter worth approximately $114,000. NEXT Financial Group Inc raised its position in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Bellwether Investment Group LLC purchased a new position in Alexion Pharmaceuticals during the second quarter worth approximately $172,000. Charlemagne Capital Ltd. purchased a new position in Alexion Pharmaceuticals during the second quarter worth approximately $191,000. Finally, Evercore Wealth Management LLC raised its position in Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares in the last quarter. 96.34% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.